Alexandria Real Estate Equities-backed exosome therapy developer Codiak Biosciences has filed to raise up to $100m having pulled back from an earlier offering last year.
Codiak Biosciences, a US-based exosome drug developer that counts life science real estate investment trust Alexandria Real Estate Equities as an investor, refiled for an initial public offering on Wednesday.
The company had previously filed to raise up to $86.3m in an offering on the Nasdaq Global Select Market in April 2019 before withdrawing its application three months later. It has now set an initial target of $100m for an IPO on the same market.
Founded in…
